Unknown

Dataset Information

0

Exploration of Structure-Activity Relationship of Aromatic Aldehydes Bearing Pyridinylmethoxy-Methyl Esters as Novel Antisickling Agents.


ABSTRACT: Aromatic aldehydes elicit their antisickling effects primarily by increasing the affinity of hemoglobin (Hb) for oxygen (O2). However, challenges related to weak potency and poor pharmacokinetic properties have hampered their development to treat sickle cell disease (SCD). Herein, we report our efforts to enhance the pharmacological profile of our previously reported compounds. These compounds showed enhanced effects on Hb modification, Hb-O2 affinity, and sickling inhibition, with sustained pharmacological effects in vitro. Importantly, some compounds exhibited unusually high antisickling activity despite moderate effects on the Hb-O2 affinity, which we attribute to an O2-independent antisickling activity, in addition to the O2-dependent activity. Structural studies are consistent with our hypothesis, which revealed the compounds interacting strongly with the polymer-stabilizing ?F-helix could potentially weaken the polymer. In vivo studies with wild-type mice demonstrated significant pharmacologic effects. Our structure-based efforts have identified promising leads to be developed as novel therapeutic agents for SCD.

SUBMITTER: Pagare PP 

PROVIDER: S-EPMC7869023 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Exploration of Structure-Activity Relationship of Aromatic Aldehydes Bearing Pyridinylmethoxy-Methyl Esters as Novel Antisickling Agents.

Pagare Piyusha P PP   Ghatge Mohini S MS   Chen Qiukan Q   Musayev Faik N FN   Venitz Jurgen J   Abdulmalik Osheiza O   Zhang Yan Y   Safo Martin K MK  

Journal of medicinal chemistry 20201118 23


Aromatic aldehydes elicit their antisickling effects primarily by increasing the affinity of hemoglobin (Hb) for oxygen (O<sub>2</sub>). However, challenges related to weak potency and poor pharmacokinetic properties have hampered their development to treat sickle cell disease (SCD). Herein, we report our efforts to enhance the pharmacological profile of our previously reported compounds. These compounds showed enhanced effects on Hb modification, Hb-O<sub>2</sub> affinity, and sickling inhibiti  ...[more]

Similar Datasets

| S-EPMC2871065 | biostudies-literature
| S-EPMC2843756 | biostudies-literature
| S-EPMC9581267 | biostudies-literature
| S-EPMC10675597 | biostudies-literature
| S-EPMC10445225 | biostudies-literature
| S-EPMC5397049 | biostudies-literature
| S-EPMC6958352 | biostudies-literature
| S-EPMC3511020 | biostudies-literature
| S-EPMC5784158 | biostudies-literature
| S-EPMC4447584 | biostudies-literature